FDA Labeling and CMC Issues on Daptomycin Products, 2021

FDA labeling and CMC issues on daptomycin products, 2021 to 2026

Daptomycin is a sterile, lyophilized cyclic lipopeptide antibiotic supplied as a single-dose vial for reconstitution and intravenous use. It reached FDA as Cubicin (NDA 021572, Cubist, 2003) and Cubicin RF, and now sits behind a crowded field of 505(b)(2) NDAs and ANDAs from Hospira, Hikma/Xellia, Sagent, Baxter (Dapzura RT), MAIA, Mylan, Fresenius Kabi, Meitheal, Accord and several Chinese and Indian sponsors. Because the molecule carries a complex impurity profile and is a parenteral product, FDA's quality (CMC) and labeling scrutiny has clustered on a predictable set of issues: impurity control and specification-setting, sterility and stability, container-closure and manufacturing-site compliance, and the readability and consistency of reconstitution/administration instructions. The findings below are drawn from Drugs@FDA review documents (including OPQ/CMC assessments and DMEPA medication-error reviews) and FDA Form 483 inspection observations, and are concentrated on decisions in the 2021 to 2026 window, with older Cubicin-era findings included only where they set the pattern reviewers still apply.

Chemistry, manufacturing and controls (CMC)

Impurities and drug-substance specifications

Impurity control is the recurring CMC theme across daptomycin applications, driven by what FDA itself calls the molecule's "complex impurity profile" ²¹.

For Hospira's daptomycin for injection (NDA 210282, original approval 2021-06-21), FDA flagged an upward trend in impurity levels in stability studies, with one impurity reaching its proposed maximum limit at 12 months at 30°C. FDA required a release limit to be added so the shelf-life limit would not be breached, and observed increases in total impurities and water with a slight decline in assay over time and temperature ¹⁹²⁰. FDA also revised the drug-product water limit during review ²⁰.
For Cubicin/Cubicin RF (NDA 021572), FDA's guidance to the sponsor set the template later applied to generics: treat characterized impurities as specified unidentified impurities, list and control each specified impurity individually in the drug-substance specification, cap any unspecified impurity at not more than 0.1%, and follow ICH Q3A format ²¹.
For Sagent's daptomycin (NDA 208385), FDA found the drug-product specification adequate except for the acceptance criteria for individual impurities/related substances and water content, and sent the assay/impurity methods to an FDA laboratory for verification because of the complex impurity profile ²⁸.
For MAIA's daptomycin for injection (NDA 217630, approved 2024-11-21), FDA treated the drug-substance specification as preliminary at filing, requested Certificates of Analysis for the drug-substance batches used to make the registration batches, and required a quantitative comparison of impurity peaks (HPLC profiles) between the proposed product and the listed drug across multiple batches ²⁵. MAIA's approach of bridging to Cubicin RF and Hospira's daptomycin to justify impurity acceptance criteria was accepted only after FDA required scientific support from stability and impurity comparisons ³²³⁴³⁵.

Stability, shelf life and freeze handling

On Hospira NDA 210282, FDA reviewed 6-month accelerated and 12-month long-term data (5°C, 25°C/60% RH, 30°C/75% RH). There were no out-of-specification results except at 40°C/75% RH, but the impurity and water increases limited the expiry: FDA supported 18 months, not the longer shelf life the sponsor proposed ¹⁹²⁰.
Because freeze-thaw studies had not been conducted, FDA required the product to be labeled "Do Not Freeze" ²⁰.
For Sagent NDA 208385, stability data were adequate except for the same impurity/related-substances and water acceptance-criteria gaps noted above ²⁸.

Sterility, endotoxin and microbiology

As expected for a parenteral, FDA reviewed sterility and bacterial endotoxin controls. For Hospira NDA 210282 the drug-product specification included sterility and endotoxin tests and was found adequate, with sterility listed as acceptable in FDA's risk table ²⁰²⁶. Sagent's NDA 208385 was found acceptable from a microbiology perspective ²⁸. These were largely resolved during review rather than becoming approval barriers.

Container-closure, extractables/leachables and elemental impurities

For Hospira NDA 210282, the product is packaged in Type I flint glass vials with gray rubber closures and aluminum seals; FDA found the container-closure system safe and suitable based on leachable data, accepted the extractables/leachables assessment (including qualification of an identified leachable), and found the ICH Q3D elemental-impurity assessment adequate ¹⁹²⁰. Container-closure was marked acceptable for sterility, particulate matter, dose uniformity and reconstitution controls in the risk table ²⁶.
Sagent's container-closure system (NDA 208385) was likewise found adequate ²⁸.

Manufacturing-site and inspection status

The most consequential CMC issue in the window was facility compliance, not the specification itself.

In the Hospira NDA 210282 review (2021-06-21), FDA recorded that the daptomycin drug-substance manufacturer had a recent CGMP inspection with a multi-item Form 483 and "remains in OAI compliance status," and that the drug-product facility (Hospira, McPherson, Kansas) had a 2016 CGMP inspection that "resulted in OAI compliance status and a Warning Letter" ¹⁸⁰. FDA's own risk table marked the manufacturing site as "Not Acceptable" because the drug-substance facility was in OAI status at the time ²⁶. The application involved a new drug-substance supplier and facility, a new drug-product site, and new container-closure suppliers on resubmission ¹⁹.
By contrast, another daptomycin application (Hikma/Xellia NDA 209949, 2017-10-20) carried an "Acceptable" facilities recommendation with no OAI notation ¹⁸¹.
FDA Form 483 observations tie the molecule to specific plant deficiencies. A Hospira (McPherson, KS) 483 from the December 2019 to January 2020 inspection cited that the completed daptomycin QA review/investigation lacked adequate impact and risk assessments required by the firm's manufacturing-investigation SOP ¹. More recently, a VA San Diego Healthcare System 483 (inspection dates April to May 2026) cited operators performing aseptic manipulations with exposed hair or skin in the ISO 5 hood, specifically during production of daptomycin 670 mg in 0.9% sodium chloride ².

No FDA warning letter naming daptomycin manufacturing was identified in this search; the enforcement signal for daptomycin sits in the OAI status and 483 observations above rather than in a product-specific warning letter.

Labeling

Reconstitution and administration instructions

The densest labeling scrutiny concerns how the prescribing information (PI) describes preparation and administration of a weight-based, multi-step parenteral.

For MAIA NDA 217630, FDA required edits so the labeling clearly stated the minimum reconstitution time and steps (wetting all powder by swirling/rotating until fully reconstituted) and the standard instruction to visually inspect for particulate matter and discoloration before administration ²⁴³¹. FDA recommended simplifying the reconstitution wording to "Reconstitute Daptomycin for Injection with Sterile Water for Injection," while retaining a separate warning against saline-based reconstitution diluents because of hyperosmotic solution/injection-site risk ³⁷. FDA also rewrote the administration directions by patient group and route (adult IV push over 2 minutes, adult infusion over 30 minutes, pediatric infusion over 30 or 60 minutes) for precision and consistency ³⁶³⁷.
Earlier, on Cubicin RF (NDA 021572, S-052, 2016), DMEPA called the proposed labeling "vulnerable to confusion" and recommended revising the Full PI, particularly Section 2.5, Preparation of Cubicin RF for Administration, including adding subheadings for readability ¹⁷.

Internal labeling inconsistencies

For MAIA NDA 217630, FDA identified an inconsistency in the diluent instructions: administration directions cited 0.9% sodium chloride only, while other PI sections cited 0.9% sodium chloride or Lactated Ringer's. FDA required subsection 2.7 to be revised so the diluent language is consistent across the PI ³⁶. FDA also edited the Highlights section to add the intended route of administration ²⁹.

Container and carton labeling

For MAIA NDA 217630, FDA required container/carton corrections including alphabetical ordering of pH adjusters / inactive ingredients (the applicant had listed hydrochloric acid and sodium hydroxide out of alphabetical order in both PI and container/carton labeling), and asked that certain wording be removed to prevent medication errors during administration ²⁹³⁰³³. FDA concluded the quality-related labeling was adequate only after these revisions ³³.
DMEPA cleared container and carton labeling for several products after iterative revisions: Baxter's Dapzura RT / daptomycin (NDA 213645) on 2021-02-25 and again on 2022-10-31 (found acceptable from a medication-error perspective) ¹⁹⁶¹⁹⁷, and Hikma/Xellia's daptomycin (NDA 217415) on 2023-01-13 ¹⁸⁸. For Cubicin RF, DMEPA concluded the product did not pose a medication-error safety concern but that labels and cartons could be improved for clarity, prominence and readability ¹⁷.

Name confusion and medication-error surveillance

In the original Cubicin review (NDA 021572, 2003), DMETS (DMEPA's predecessor) found the labeling would not by itself prevent misinterpretation of a look-alike/sound-alike prescription and warned that the package insert should not be the primary tool for educating practitioners ¹⁸. It flagged potential confusion with Ambien, Calcium, Librium and Eulexin beyond the sponsor's own analysis of Cleocin, and recommended the sponsor report proprietary-name-confusion medication errors for three years rather than one ¹⁸. These name-confusion concerns predate the current window but explain the sustained DMEPA attention to daptomycin cartons and labels through 2023.

What the pattern tells a reviewer

For daptomycin specifically, FDA's quality expectations now function as a de facto template: identify and individually control each specified impurity to ICH Q3A, justify impurity acceptance criteria by direct HPLC comparison to the listed drug across multiple batches, support shelf life against upward impurity/water trends, and confirm facility CGMP status before approval (the Hospira OAI episode shows how a drug-substance site in OAI can move a whole application to "Not Acceptable" on the risk table) ²¹¹⁹²⁵²⁶¹⁸⁰. On labeling, the constant is the preparation/administration section: reconstitution wording, diluent consistency across PI sections, particulate-inspection language, and alphabetical excipient ordering on cartons ²⁴³⁶³⁷³⁰. Sponsors filing new daptomycin ANDAs or 505(b)(2) NDAs should expect FDA to raise these same points.

A reader who needs to go deeper can ask Rhizome for the full CMC review text of a specific application (for example the Hospira NDA 210282 OPQ assessment or the MAIA NDA 217630 DMEPA memo), the complete Form 483 observations for a named facility, or a side-by-side of impurity acceptance criteria across the daptomycin generics.

FDA Labeling and CMC Issues on Daptomycin Products, 2021–2026